

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Tagrisso (osimertinib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Tagrisso (osimertinib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Tagrisso (osimertinib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of Metastatic Non-Small Cell Lung cancer (NSCLC) disease;
AND
- II. Individual has tumors with EGFR exon 19 deletions or exon 21 L858R mutations, and results are confirmed; **AND**
- III. Individual is using as first-line treatment;

OR

- IV. Individual has a diagnosis of Metastatic Non-Small Cell Lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) T790M mutation present and results are confirmed;
AND
- V. Individual has progressed on or after EGFR tyrosine kinase inhibitor therapy (such as afatinib, gefitinib, erlotinib);

OR

- VI. Individual has a diagnosis of Central Nervous System Cancers, for recurrent brain metastases if active against the primary tumor (NSCLC) (NCCN 2A).

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: 4/2018.

DrugPoints® System [Internet Database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.